What is the antinuclear antibody (ANA) profile by immunoblot, its diagnostic accuracy, and what other methods are available for ANA detection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ANA Profile by Immunoblot

Immunoblot (also called line immunoassay or LIA) is a solid-phase assay that detects specific antinuclear antibodies against a limited panel of purified or recombinant antigens, but it should not be used as the primary ANA screening method—indirect immunofluorescence assay (IIFA) on HEp-2 cells remains the reference standard for initial ANA detection 1.

What is ANA Profile by Immunoblot?

Immunoblot for ANA testing uses strips coated with individual purified or synthetic autoantigens (such as Ro-52, SS-A, SS-B, Sm, RNP, Scl-70, Jo-1, centromere proteins, and others). Patient serum is applied to these strips, and specific antibodies bind to their corresponding antigens, producing visible bands that identify which specific autoantibodies are present 1.

Key characteristics:

  • Tests a limited, predefined panel of specific antigens (typically 10-15 specificities)
  • Provides qualitative or semi-quantitative results for individual antibodies
  • Cannot detect antibodies to antigens not included on the strip
  • Does not provide pattern information like IIFA does
  • Designed as a confirmatory or reflex test, not a screening tool

Diagnostic Accuracy

The accuracy of immunoblot varies significantly depending on the specific antibody being tested and the clinical context:

Overall Performance

  • Specificity: 77.0% for SARD diagnosis 2
  • Sensitivity: 75.3% for SARD diagnosis 2
  • Area under curve (AUC): 0.761 2

Critical Limitation - Anti-dsDNA Detection

Immunoblot performs poorly for anti-dsDNA antibodies, showing only 19.8% sensitivity for SLE diagnosis compared to 58.1% for multiplex bead-based assays 2. This is a significant clinical pitfall when using immunoblot for lupus evaluation.

Agreement Between Methods

Immunoblot shows substantial to excellent agreement with other methods for most specific antibodies:

  • Good agreement (kappa 0.66-0.74): SS-B antibodies 3
  • Moderate agreement (kappa 0.51-0.69): RNP, Sm antibodies 3
  • Poor agreement: SS-A/Ro antibodies despite high prevalence 3
  • No agreement: Scl-70 antibodies between different immunoblot platforms 4

Important Caveats

  • 9% of ANA-negative patients by IIFA can still be ENA-positive by immunoblot 5, highlighting method discordance
  • Performance is highly dependent on the specific manufacturer and antigen panel used
  • Cannot detect antibodies to antigens not included on the strip (unlike IIFA which detects all cellular antibodies)

Other Available Methods for ANA Detection

1. Indirect Immunofluorescence Assay (IIFA) on HEp-2 Cells - REFERENCE STANDARD

This is the gold standard and recommended screening method 1, 6.

Advantages:

  • Detects antibodies to all cellular antigens (nuclear, cytoplasmic, mitotic)
  • Provides pattern information (homogeneous, speckled, nucleolar, centromere, cytoplasmic) that guides further testing
  • Highest sensitivity: 86.5% for SARD 2
  • Included in classification criteria for multiple autoimmune diseases

Disadvantages:

  • Lower specificity: 67.6% 2
  • Requires skilled technicians for visual interpretation
  • Labor-intensive with serial dilutions
  • Subject to inter-observer variability
  • Up to 25% of healthy individuals can be positive at 1:40 dilution 1

Optimal screening dilution: 1:160 for adults (represents 95th percentile of healthy controls) 1

2. Multiplex Bead-Based Immunoassay (MBA)

Examples include BioPlex 2200 ANA Screen.

Performance:

  • Best overall diagnostic performance: AUC 0.814 2
  • Specificity: 83.8% 2
  • Sensitivity: 79.0% 2
  • Superior to immunoblot for anti-dsDNA detection (58.1% vs 19.8% sensitivity) 2

Advantages:

  • Automated, high-throughput
  • Quantitative results
  • Better standardization than IIFA
  • Excellent agreement with immunoblot for most antibodies (kappa 0.71-0.98) 2

Disadvantages:

  • Limited to predefined antigen panel
  • No pattern information
  • Cannot detect antibodies to antigens not on the panel

3. ELISA (Enzyme-Linked Immunosorbent Assay)

Performance:

  • Good concordance with IIFA for total ANA screening 4
  • Excellent agreement with CIE for Scl-70 antibodies (kappa 1.00) 3
  • Good agreement for RNP, Sm, SS-B antibodies (kappa 0.51-0.60) 3

Advantages:

  • Quantitative results
  • Automated
  • Cost-effective for high-volume testing

Disadvantages:

  • Limited antigen panel
  • No pattern information
  • Variable performance for different antibodies

4. Chemiluminescence Immunoassay (CLIA)

Newer automated platform mentioned in guidelines 1.

Advantages:

  • Fully automated
  • High throughput
  • Quantitative

Disadvantages:

  • Limited published data on clinical performance
  • Restricted antigen panel

5. Computer-Assisted Diagnosis (CAD) Systems for IIFA

Emerging technology that automates IIFA reading 6.

Advantages:

  • Reduces inter-observer variability
  • Maintains IIFA's comprehensive antigen detection
  • Improves standardization

Status: Still requires validation but shows promise for harmonization

Recommended Testing Algorithm

Based on international consensus recommendations 1, 6:

  1. Initial screening: IIFA on HEp-2 cells at 1:160 dilution

    • If negative and clinical suspicion remains low: stop
    • If negative but high clinical suspicion for specific disease: consider reflex testing for disease-specific antibodies

  2. If IIFA positive:

    • Report titer and pattern
    • Perform reflex testing for specific antibodies based on pattern:
      • Homogeneous → anti-dsDNA, anti-histone
      • Speckled → anti-ENA panel (Sm, RNP, SS-A, SS-B)
      • Nucleolar → anti-Scl-70, anti-RNA polymerase III
      • Centromere → anti-centromere proteins
      • Cytoplasmic → anti-Jo-1, anti-mitochondrial

  3. Confirmatory testing: Use immunoblot, MBA, or ELISA for specific antibody identification

    • Avoid immunoblot as sole method for anti-dsDNA (use Crithidia luciliae IIF or ELISA instead)

  4. For high-volume laboratories: MBA or ELISA may be used for screening if clearly labeled as such (not as "ANA test") and validated against IIFA 1

Critical Clinical Pitfalls

  • Never rely on immunoblot alone for screening—it will miss antibodies not on the panel 1
  • Immunoblot is inadequate for anti-dsDNA detection in SLE—use alternative methods 2
  • Method must be specified in reports—clinicians may incorrectly assume IIFA was performed 1
  • Positive results require clinical correlation—up to 25% of healthy individuals have positive ANA 1
  • Reflex testing reduces unnecessary costs—implementing algorithms saved €121,000 annually in one study 7
  • High titers (≥1:640) without autoimmune disease associate with liver disorders—consider alternative diagnoses 8

References

6
Research

Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP.

Clinical chemistry and laboratory medicine, 2023

Related Questions

When should antinuclear antibody (ANA) testing be performed by indirect immunofluorescence assay (IFA), by enzyme‑linked immunosorbent assay (ELISA)/enzyme immunoassay (EIA), or by line immunoassay (LIA) ANA profile, and what are the practical advantages, limitations, and ideal testing sequence for each method?
When is it appropriate to order an antinuclear antibody IgG enzyme-linked immunosorbent assay (ANA IgG ELISA)?
What is the clinical significance of a cytoplasmic fibrillar antinuclear antibody (ANA) pattern at a titer of 1:100?
What is the likely diagnosis for a 61-year-old woman with a 7-month history of diffuse bilateral pain in the hands, shoulders, knees, feet, and jaw, accompanied by chronic fatigue, sleep disturbances, depression, headaches, weight gain, and left-sided pain, with normal X‑rays and a positive antinuclear antibody (ANA)?
What is the significance of a positive antinuclear antibody (ANA) titer of 1:100 with a speckled pattern, and what further evaluation or management is recommended?
What is the appropriate sublingual estradiol dose for a postmenopausal patient switching from oral estradiol 0.5 mg daily?
In a pediatric patient with enlarged cervical lymph node swelling, fever, intermittent weight loss, and anemia, what is the best diagnostic step?
What dexamethasone dose and schedule should be given intravenously (or intramuscularly) to a 42‑kg patient with meningitis?
How does primary hyperparathyroidism lead to elevated low-density lipoprotein (LDL) cholesterol?
What is the recommended regimen for augmenting valproic acid with quetiapine (Seroquel) in a patient with psychosis?
Can valproate be added to quetiapine (Seroquel) for a patient with schizophrenia who has persistent mood symptoms or inadequate response?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.